COLNGITE PRIMARIA BILIARE: UN ALTRO PPRA (dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist) IN SECONDA LINEA, ELAFIBRANOR. UN TRIAL MULTICENTRICO DA”THE NEW ENGLAND JOURNAL OF MEDICINE”

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis Kris V. Kowdley et al. Abstract BACKGROUND Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have…

GLI AGONISTI PPAR NELLA COLANGITE PRIMARIA BILIARE. UN GRANDE EDITORIALE 2024 DAL “NEW ENGLAND JOURNAL OF MEDICINE”

PPAR Agonists in Primary Biliary Cholangitis Bernd Schnabl, M.D. Kowdley et al.1 and Hirschfield et al.2 now report in the Journal the results of trials of elafibranor and seladelpar, respectively, for the treatment of primary biliary cholangitis, a chronic liver disease that affects the bile ducts. Both drugs are peroxisome proliferator–activated receptor (PPAR) agonists, and the results support their…

INFLIXIMAB PER IL MANTENIMENTO DELLA REMISSIONE NEL CROHN. L’ULTIMA REVISIONE 2024 DALLA “COCHRANE LIBRARY” (FREE)

Infliximab for maintenance of medically-induced remission in Crohn’s disease (Review) Gordon M, Sinopoulou et al. Background Infliximab is a monoclonal antibody that binds and neutralises tumour necrosis factor-alpha (TNF-α) which is present in high levels in the blood serum, mucosa and stool of patients with Crohn’s disease. Objectives To determine the efficacy and safety of…

IBD: BIOLOGICI E SMALL MOLECULES. TRA EBM E REAL WORLD EVIDENCE: UN’OTTIMA INTEGRAZIONE PER SCEGLIERE LA TERAPIA CORRETTA PER IL VS PAZIENTE. DA “GASTROENTEROLOGY” (FREE)

Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases Parambir S. Dulai et al. Figure 1 Comparison of RCTs with RWE observational studies studying comparative effectiveness and safety of 2 therapies in IBD. In contrast to highly selected participants in RCTs, where the act of randomization balances both measurable and unmeasurable…

ULTIME RACCOMANDAZIONI STATISTICHE 2024 PER IL VOSTRO PAPER ! LEGGETE PER FAVORE ! DA “THE LANCET” (FREE)

Recommendations for accurate reporting in medical research statistics Mohammad Ali Mansournia, Maryam Nazemipou Recommendations for accurate reporting in medical research statistics An important requirement for validity of medical research is sound methodology and statistics, yet this is still often overlooked by medical researchers.1,2 Based on the experience of reviewing statistics in more than 1000 manuscripts…